PX-3

PX-3

Systematic (IUPAC) name
N-(2-amino-1-benzyl-2-oxo-ethyl)-1-(cyclohexylmethyl)indazole-3-carboxamide
Clinical data
Legal status	CA: Schedule II
Identifiers
CAS Number	1185887-14-2
PubChem	CID: 70969676
UNII	3877T06H05 Y
Chemical data
Formula	C24H28N4O2
Molecular mass	404.5 g/mol
SMILES O=C(N[C@H](C(N)=O)CC1=CC=CC=C1)C2=NN(CC3CCCCC3)C4=C2C=CC=C4
InChI InChI=1S/C24H28N4O2/c25-23(29)20(15-17-9-3-1-4-10-17)26-24(30)22-19-13-7-8-14-21(19)28(27-22)16-18-11-5-2-6-12-18/h1,3-4,7-10,13-14,18,20H,2,5-6,11-12,15-16H2,(H2,25,29)(H,26,30)/t20-/m0/s1 Key:DMHWDSGURMXMGE-FQEVSTJZSA-N

PX-3 (also known as APP-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB₁ receptor with a binding affinity of Ki = 47.6 nM and was originally developed by Pfizer in 2009 as an analgesic medication.

The acronym 'APP' signifies the 'amino', 'phenyl' and 'propanone' elements of the structure. Three related compounds, PX-1 (5F-APP-PICA, SRF-30), PX-2 (5F-APP-PINACA, FU-PX) and APP-FUBINACA were reported by the EMCDDA in late 2014.

Legality

Sweden's public health agency suggested to classify APP-CHMINACA as hazardous substance on June 1, 2015.

See also

• 5F-AB-PINACA
• 5F-ADB
• 5F-AMB
• 5F-APINACA
• AB-FUBINACA
• AB-CHFUPYCA
• AB-CHMINACA
• AB-PINACA
• ADB-CHMINACA
• ADB-FUBINACA
• ADB-PINACA
• ADBICA
• APICA
• APINACA
• MDMB-CHMICA
• PX-1
• PX-2